Skip to main content
. 2023 Aug 25;26(1):55–67. doi: 10.1093/neuonc/noad155

Figure 3.

Figure 3.

Sirt2i selectively promotes cellular senescence and impairs ATRX-deficient GSC tumor growth in vivo. (A) Growth curves for TS543 shATRX flank xenografts in mice treated with vehicle or AK7 (40 mg/kg daily following engraftment) (N=5 per group). (B) Quantified immunofluorescence staining showing decreased proliferation (MIB1) and increased expression of senescence markers (p16 and SEMA3F) in AK7-treated explanted TS543 shATRX xenografts versus vehicle-treated controls. (C) Growth curves for TS543 flank xenografts in mice treated with vehicle or AK7 (40 mg/kg daily following engraftment) (N=5 per group). (D) Quantified immunofluorescence staining showing expression of MIB1 and senescence markers (p16 and SEMA3F) in AK7 or vehicle-treated explanted TS543 xenografts. (E) Representative immunofluorescence images of immunofluorescence studies in xenografts (60x magnification). Where applicable, error bars reflect SEM; p values determined by unpaired, two-tailed t-test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and ns = not significant).